Table 2.
Clinicopathological parameters and uPAR levels in tumour tissues and in plasma of patients with chondrosarcoma.
| Patients | First clinical evaluation | Therapy | Survival from diagnosis (months) | uPAR gradinga | SuPAR (pg/mL)b |
|---|---|---|---|---|---|
| 1 | P | Surgery | 6 | 0 | 1094 |
| 2 | P | Surgery | 87 | 1 | 1.508 |
| 3 | P + Lung M | Surgery | 3 | 3 | 3.645 |
| 4 | P + Lung M | Neoadiuvant chemotherapy and surgery | 14 | 3 | 5.152 |
| 5 | P | Surgery | 9 | 2 | 1.556 |
| 6 | P + Lung M | Surgery and chemotherapy | 8 | 3 | ND |
P, primary tumor; M, metastasis; aImmunohistochemical staining of tumor frozen sections with R4 anti-uPAR mAb was graded as absent (grading 0), faint (grading 1), moderate (grading 2), or intense (grading 3). bDetermination of plasmatic SuPAR content by Elisa, expressed as pg SuPAR/mL plasma.